Abstract：
Population-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0-35.3) and 4.6 (95% CI: 3.1-6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.
摘要：
基于人群的研究表明，患第二种癌症的风险很高，尤其是皮肤，在慢性淋巴细胞白血病（CLL）患者中。我们描述了接受至少两行治疗的复发性/难治性CLL的澳大利亚患者中第二原发性恶性肿瘤（SPM）的年龄标准化发生率（SIR）。包括ibrutinib.从2014年12月至2017年11月，从澳大利亚淋巴瘤和相关疾病登记处的13个地点确定了156名患者。111有关于SPM率的随访数据。伊布鲁替尼治疗开始后38.4个月，25%经历过任何SPM。黑色素瘤和所有癌症（不包括非黑色素瘤性皮肤癌）的SIR分别为15.8（95％置信区间（CI）：7.0-35.3）和4.6（95％CI：3.1-6.9）。这些数据突出了初级预防性干预和监测的重要性，特别是随着CLL的生存率不断提高。
